Brainsway Ltd (BWAY)
BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21
BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21
📉 **NEGATIVE** • Low confidence analysis (45%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (25%) **Content type:** Clinical